CytomX Therapeutics Inc Dividends
The next dividend date for CytomX Therapeutics Inc has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for CytomX Therapeutics Inc (CTMX)
More About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Owning CytomX Therapeutics Inc Stock on the Dividend Date
If you own CytomX Therapeutics Inc stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of CytomX Therapeutics Inc stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of CytomX Therapeutics Inc stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying CytomX Therapeutics Inc stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the CytomX Therapeutics Inc dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Learning More CytomX Therapeutics Inc Dividends
You can contact us any time if you would like to ask questions about CytomX Therapeutics Inc dividends or anything else related to the stock market.